Agomelatine is a melatonin receptor agonist and 5-HT2C receptor antagonist that can correct circadian rhythm disorders and re-establish rhythms, and has shown antidepressant effects in animal models of depression; it specifically increases the release of norepinephrine and dopamine in the prefrontal cortex, and has no significant effect on monoamine reuptake; it has a positive phase-adjusting effect on the human body, inducing an advance in the sleep phase, lowering body temperature, and inducing a melatonin-like effect.

It can bind to hydroxyapatite in bones and inhibit bone resorption. At the cellular level, this product inhibits osteoclasts. It reduces the absorption of bone turnover and bone remodeling sites, inhibits osteoclasts in osteoporosis model rats and miniature pigs, and increases bone mass and bone biomechanical strength in a dose-dependent manner. The increase in bone density is related to the efficacy.

Extract from the above information

This non-sulfonylurea insulin secretagogue specifically binds to the 36KDA protein on the ATP-dependent potassium ion channel outside the insulin cell membrane, closing the potassium channel, depolarizing the cell, opening the calcium channel, and causing calcium ion influx, thus promoting insulin secretion. It works faster than sulfonylureas, so it has a faster effect in lowering blood sugar after a meal.

Pharmacological action not specified